Literature DB >> 26099018

The TET2 interactors and their links to hematological malignancies.

Feng Pan1,2, Ophelia Weeks1, Feng-Chun Yang2,3, Mingjiang Xu2,3.   

Abstract

Ten-eleven translocation (TET) family proteins are dioxygenases that oxidize 5-methylcytosine to 5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine in DNA, early steps of active DNA demethylation. TET2, the second member of TET protein family, is frequently mutated in patients with hematological malignancies, leading to aberrant DNA methylation profiling and decreased 5hmC levels. Located in the nucleus and acting as a DNA-modifying enzyme, TET2 is thought to exert its function via TET2-containing protein complexes. Identifying the interactome network of TET2 likely holds the key to uncover the mechanisms by which TET2 exerts its function in cells. Here, we review recent literature on TET2 interactors and discuss their possible roles in TET2 loss-mediated dysregulation of hematopoiesis and pathogenesis of hematological malignancies.
© 2015 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  human molecular disease; molecular genetics; protein function; proteonomics

Mesh:

Substances:

Year:  2015        PMID: 26099018      PMCID: PMC4765929          DOI: 10.1002/iub.1389

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  72 in total

1.  A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.

Authors:  Oreofe Odejide; Oliver Weigert; Andrew A Lane; Dan Toscano; Matthew A Lunning; Nadja Kopp; Sunhee Kim; Diederik van Bodegom; Sudha Bolla; Jonathan H Schatz; Julie Teruya-Feldstein; Ephraim Hochberg; Abner Louissaint; David Dorfman; Kristen Stevenson; Scott J Rodig; Pier Paolo Piccaluga; Eric Jacobsen; Stefano A Pileri; Nancy L Harris; Simone Ferrero; Giorgio Inghirami; Steven M Horwitz; David M Weinstock
Journal:  Blood       Date:  2013-12-17       Impact factor: 22.113

2.  An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis.

Authors:  Jijun Cheng; Shangqin Guo; Suning Chen; Stephen J Mastriano; Chaochun Liu; Ana C D'Alessio; Eriona Hysolli; Yanwen Guo; Hong Yao; Cynthia M Megyola; Dan Li; Jun Liu; Wen Pan; Christine A Roden; Xiao-Ling Zhou; Kartoosh Heydari; Jianjun Chen; In-Hyun Park; Ye Ding; Yi Zhang; Jun Lu
Journal:  Cell Rep       Date:  2013-10-10       Impact factor: 9.423

3.  Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma.

Authors:  Fazila Asmar; Vasu Punj; Jesper Christensen; Marianne T Pedersen; Anja Pedersen; Anders B Nielsen; Christoffer Hother; Ulrik Ralfkiaer; Peter Brown; Elisabeth Ralfkiaer; Kristian Helin; Kirsten Grønbæk
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

4.  Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.

Authors:  Lulu Hu; Ze Li; Jingdong Cheng; Qinhui Rao; Wei Gong; Mengjie Liu; Yujiang Geno Shi; Jiayu Zhu; Ping Wang; Yanhui Xu
Journal:  Cell       Date:  2013-12-05       Impact factor: 41.582

5.  Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells.

Authors:  Yun Huang; Lukas Chavez; Xing Chang; Xue Wang; William A Pastor; Jinsuk Kang; Jorge A Zepeda-Martínez; Utz J Pape; Steven E Jacobsen; Bjoern Peters; Anjana Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

6.  Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis.

Authors:  Jozef Madzo; Hui Liu; Alexis Rodriguez; Aparna Vasanthakumar; Sriram Sundaravel; Donne Bennett D Caces; Timothy J Looney; Li Zhang; Janet B Lepore; Trisha Macrae; Robert Duszynski; Alan H Shih; Chun-Xiao Song; Miao Yu; Yiting Yu; Robert Grossman; Brigitte Raumann; Amit Verma; Chuan He; Ross L Levine; Don Lavelle; Bruce T Lahn; Amittha Wickrema; Lucy A Godley
Journal:  Cell Rep       Date:  2013-12-27       Impact factor: 9.423

7.  Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.

Authors:  Mamiko Sakata-Yanagimoto; Terukazu Enami; Kenichi Yoshida; Yuichi Shiraishi; Ryohei Ishii; Yasuyuki Miyake; Hideharu Muto; Naoko Tsuyama; Aiko Sato-Otsubo; Yusuke Okuno; Seiji Sakata; Yuhei Kamada; Rie Nakamoto-Matsubara; Nguyen Bich Tran; Koji Izutsu; Yusuke Sato; Yasunori Ohta; Junichi Furuta; Seiichi Shimizu; Takuya Komeno; Yuji Sato; Takayoshi Ito; Masayuki Noguchi; Emiko Noguchi; Masashi Sanada; Kenichi Chiba; Hiroko Tanaka; Kazumi Suzukawa; Toru Nanmoku; Yuichi Hasegawa; Osamu Nureki; Satoru Miyano; Naoya Nakamura; Kengo Takeuchi; Seishi Ogawa; Shigeru Chiba
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 41.307

8.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Authors:  T Haferlach; Y Nagata; V Grossmann; Y Okuno; U Bacher; G Nagae; S Schnittger; M Sanada; A Kon; T Alpermann; K Yoshida; A Roller; N Nadarajah; Y Shiraishi; Y Shiozawa; K Chiba; H Tanaka; H P Koeffler; H-U Klein; M Dugas; H Aburatani; A Kohlmann; S Miyano; C Haferlach; W Kern; S Ogawa
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528

9.  Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.

Authors:  Omar Abdel-Wahab; Jie Gao; Mazhar Adli; Anwesha Dey; Thomas Trimarchi; Young Rock Chung; Cem Kuscu; Todd Hricik; Delphine Ndiaye-Lobry; Lindsay M Lafave; Richard Koche; Alan H Shih; Olga A Guryanova; Eunhee Kim; Sheng Li; Suveg Pandey; Joseph Y Shin; Leon Telis; Jinfeng Liu; Parva K Bhatt; Sebastien Monette; Xinyang Zhao; Christopher E Mason; Christopher Y Park; Bradley E Bernstein; Iannis Aifantis; Ross L Levine
Journal:  J Exp Med       Date:  2013-11-11       Impact factor: 14.307

10.  Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.

Authors:  Tomoya Muto; Goro Sashida; Motohiko Oshima; George R Wendt; Makiko Mochizuki-Kashio; Yasunobu Nagata; Masashi Sanada; Satoru Miyagi; Atsunori Saraya; Asuka Kamio; Genta Nagae; Chiaki Nakaseko; Koutaro Yokote; Kazuya Shimoda; Haruhiko Koseki; Yutaka Suzuki; Sumio Sugano; Hiroyuki Aburatani; Seishi Ogawa; Atsushi Iwama
Journal:  J Exp Med       Date:  2013-11-11       Impact factor: 14.307

View more
  11 in total

1.  Sclerosing Polycystic Adenoma: Conclusive Clinical and Molecular Evidence of Its Neoplastic Nature.

Authors:  Juan C Hernandez-Prera; Daryoush Saeed-Vafa; Amin Heidarian; Kathleen Gewandter; Kristen Otto; Bruce M Wenig
Journal:  Head Neck Pathol       Date:  2021-08-19

Review 2.  Mechanisms that regulate the activities of TET proteins.

Authors:  Kanak Joshi; Shanhui Liu; Peter Breslin S J; Jiwang Zhang
Journal:  Cell Mol Life Sci       Date:  2022-06-15       Impact factor: 9.207

3.  Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.

Authors:  Y Lyu; J Lou; Y Yang; J Feng; Y Hao; S Huang; L Yin; J Xu; D Huang; B Ma; D Zou; Y Wang; Y Zhang; B Zhang; P Chen; K Yu; E W-F Lam; X Wang; Q Liu; J Yan; B Jin
Journal:  Leukemia       Date:  2017-04-12       Impact factor: 11.528

4.  Increased 5-hydroxymethylcytosine and Ten-eleven Translocation Protein Expression in Ultraviolet B-irradiated HaCaT Cells.

Authors:  Dan Wang; Jin-Hua Huang; Qing-Hai Zeng; Can Gu; Shu Ding; Jian-Yun Lu; Jing Chen; Sheng-Bo Yang
Journal:  Chin Med J (Engl)       Date:  2017-03-05       Impact factor: 2.628

5.  TET1-mediated DNA hydroxymethylation activates inhibitors of the Wnt/β-catenin signaling pathway to suppress EMT in pancreatic tumor cells.

Authors:  Jian Wu; Hongzhe Li; Minmin Shi; Youwei Zhu; Yang Ma; Yiming Zhong; Cheng Xiong; Hao Chen; Chenghong Peng
Journal:  J Exp Clin Cancer Res       Date:  2019-08-09

6.  Downregulation of TET1 Promotes Bladder Cancer Cell Proliferation and Invasion by Reducing DNA Hydroxymethylation of AJAP1.

Authors:  Yi-Lin Yan; Zheng-Nan Huang; Zhen Zhu; Yang-Yan Cui; Mei-Qian Li; Rui-Min Huang; Jun Yan; Bing Shen
Journal:  Front Oncol       Date:  2020-05-21       Impact factor: 6.244

Review 7.  Tet2 at the interface between cancer and immunity.

Authors:  Shuai Jiang
Journal:  Commun Biol       Date:  2020-11-12

8.  CGB5 expression is independently associated with poor overall survival and recurrence-free survival in patients with advanced gastric cancer.

Authors:  Yuxin Yang; Yonghong Shi; Yanjuan Hou; Ying Lu; Jinliang Yang
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

9.  Epigenetic dysregulation of TET2 in human glioblastoma.

Authors:  María G García; Antonella Carella; Rocío G Urdinguio; Gustavo F Bayón; Virginia Lopez; Juan Ramón Tejedor; Marta I Sierra; Estela García-Toraño; Pablo Santamarina; Raúl F Perez; Cristina Mangas; Aurora Astudillo; M Daniela Corte-Torres; Inés Sáenz-de-Santa-María; María-Dolores Chiara; Agustín F Fernández; Mario F Fraga
Journal:  Oncotarget       Date:  2018-05-25

10.  Tet2 Regulates Osteoclast Differentiation by Interacting with Runx1 and Maintaining Genomic 5-Hydroxymethylcytosine (5hmC).

Authors:  Yajing Chu; Zhigang Zhao; David Wayne Sant; Ganqian Zhu; Sarah M Greenblatt; Lin Liu; Jinhuan Wang; Zeng Cao; Jeanette Cheng Tho; Shi Chen; Xiaochen Liu; Peng Zhang; Jaroslaw P Maciejewski; Stephen Nimer; Gaofeng Wang; Weiping Yuan; Feng-Chun Yang; Mingjiang Xu
Journal:  Genomics Proteomics Bioinformatics       Date:  2018-06-13       Impact factor: 7.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.